HealthcareServices

Global Chronic Liver Diseases Therapeutics Market Overview: Trends Shaping Growth to 2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Chronic Liver Diseases Therapeutics Industry In 2025?

The chronic liver diseases therapeutics market has experienced significant expansion in recent years. It is projected to increase from $14.38 billion in 2024 to $15.88 billion by 2025, achieving a compound annual growth rate (CAGR) of 10.4%. This historical growth can be attributed to several factors, including the increasing incidence of viral hepatitis, rising obesity rates, an aging global population, enhanced awareness of liver health, and improved patient access to available treatments.

The chronic liver diseases therapeutics market is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $23.63 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.5%. This growth is primarily attributed to an increased emphasis on personalized medicine, an expanding array of novel therapies in development, the proliferation of telemedicine and digital health solutions, a heightened demand for liver disease prevention initiatives, and the increasing prevalence of viral hepatitis. Key trends shaping the market include the incorporation of artificial intelligence in diagnostics, advancements in biologics and gene therapies, the emergence of non-invasive treatment alternatives, the adoption of combination therapies, and the broader implementation of patient-focused care approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp

What Are The Drivers Pushing New Developments In The Chronic Liver Diseases Therapeutics Market?

The chronic liver disease therapeutics market is projected to expand, primarily propelled by increasing alcohol consumption. Alcohol consumption entails ingesting beverages that contain ethanol, spanning from moderate to excessive use, which can lead to various health consequences. The global rise in alcohol consumption is attributed to factors like growing social acceptance, increasing incomes, and greater accessibility worldwide. Therapeutics for chronic liver disease are essential for managing liver damage resulting from excessive alcohol consumption, helping to slow disease progression and enhance liver function. For instance, in June 2024, according to the First Citizens Bank, a US financial institution, direct-to-consumer (DTC) wine case sales saw a 1.2% increase in 2023 compared to 2022. Additionally, in December 2023, a report published by Kirin Holdings Company Limited, a Japan-based beverage company, noted that approximately 192.1 million kiloliters of beer were consumed in 2022, representing a 2.9% increase from the previous year. Consequently, the rising alcohol consumption is a key factor driving the growth of the chronic liver disease therapeutics market.

What Are The Major Segment Types Covered In The Chronic Liver Diseases Therapeutics Market?

The chronic liver diseases therapeuticsmarket covered in this report is segmented –

1) By Treatment Type: Antiviral Drugs; Immunosuppressants Vaccines; Immunoglobulins; Corticosteroids; Targeted Therapy; Chemotherapy

2) By Disease Type: Hepatitis; Autoimmune Diseases; Non-Alcoholic Fatty Liver Disease; Cancer; Genetic Disorders

3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues; Interferons; Direct-Acting Antivirals

2) By Immunosuppressants: Calcineurin Inhibitors; mTOR Inhibitors; Purine Synthesis Inhibitors

3) By Vaccines: Hepatitis A Vaccine; Hepatitis B Vaccine; Combination Hepatitis Vaccines

4) By Immunoglobulins: Hepatitis B Immune Globulin; Intravenous Immunoglobulin

5) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone

6) By Targeted Therapy: Tyrosine Kinase Inhibitors; Monoclonal Antibodies

7) By Chemotherapy: Systemic Chemotherapy; Transarterial Chemoembolization Agents

Which Competitive Trends Are Defining The Chronic Liver Diseases Therapeutics Market Structure?

Leading companies in the chronic liver diseases therapeutics market are concentrating on developing advanced innovations, such as RNA therapies, to address underlying genetic and molecular mechanisms, thereby providing more effective and personalized treatment choices. RNA therapies represent sophisticated medical treatments that employ RNA molecules to regulate gene expression or protein production, aiming to treat or prevent diseases by targeting specific genetic pathways. For example, in May 2022, Ochre Bio, a UK-based biotech company, inaugurated its groundbreaking ‘Liver ICU’ research facility at BioLabs@NYULangone, a biopharma incubator located in New York City. This modern site evaluates the efficacy of next-generation RNA therapeutics using whole human livers maintained on perfusion machines. By utilizing discarded donor livers for research, the facility seeks to accelerate drug development timelines and enhance the precision of liver treatment studies through the replication of human physiological conditions.

Who Are The Key Multinational Companies Dominating The Chronic Liver Diseases Therapeutics Market?

Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-liver-diseases-therapeutics-global-market-report

How Do Regional Market Performances Compare Within The Chronic Liver Diseases Therapeutics Industry?

North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21145&type=smp

Browse Through More Reports Similar to the Global Chronic Liver Diseases Therapeutics Market 2025, By The Business Research Company

Chronic Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795